Men's Health Latest News
The PLCO trial's conclusion that routine PSA testing does not affect prostate cancer mortality risk could be wrong.
Findings support the use of a 5 grade-group system that more accurately reflects patient risk of adverse outcomes.
The odds of PSA screening were higher among blacks than non-Hispanic whites.
PSA level declined by an average of 0.68 ng/mL in the treatment group.
Researchers found an adjusted 68% decreased risk of prostate cancer in men with IBD who used aminosalicylate.
An early, integrated approach led to less deterioration of erectile function after surgery.
Almost quadruple the risk found among Asian men with erectile dysfunction.
Testosterone levels of 20 ng/dL or less were achieved and maintained by more than 90% of men with advanced prostate cancer.
Molecular pathways identified that may serve as potential biomarkers in prostate cancer treated with stereotactic body radiation therapy (SBRT).
Metformin, a widely used oral anti-diabetic drug, enhanced the anti-prostate cancer activity of abiraterone and enzalutamide.
Fewer prostate cancer deaths may be yet another benefit of smoking cessation.
Prostate cancer patients with 2 or more comorbid diseases are more likely to have their cancer upgraded and up staged at RP.
A PSA nadir below 0.4 ng/mL offers the best long-term biochemical progression-free survival, study shows.
Study points to a need for caution in using active surveillance for men with Gleason 7 disease.
Older men whose clinician was a physician trainee had substantially lower prostate-specific antigen (PSA) screening rates.
Men's Health Videos
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)